MTHFR A1298C: frequently asked questions

MTHFR A1298C is one of the two common inherited variants of the MTHFR gene — the gene for 5,10-methylenetetrahydrofolate reductase, the enzyme that produces 5-methyltetrahydrofolate, the predominant circulatory form of folate and the methyl carbon donor that turns homocysteine back into methionine. A1298C is database name rs1801131, modern notation c.1286A>C (p.Glu429Ala): a single-base change in exon 7, inside the enzyme’s C-terminal regulatory domain — the domain that binds SAM, the enzyme’s own allosteric brake. It was discovered in 1998 by two groups independently. Carriers are not “broken”: homozygous carriers retain roughly 60% of control enzyme activity in cell extracts, the purified variant protein behaves indistinguishably from the normal enzyme in a test tube, and most carriers never know they carry it.

Very common, and unevenly distributed by ancestry. In gnomAD exomes (retrieved 2026-08-09) the 1298C allele frequency is about 0.307 globally — meaning roughly 43% of people carry at least one copy and about 9–10% of Europeans carry two (1298CC). It is most frequent in South Asian (0.411) and Middle Eastern (0.373) populations, least frequent in African/African-American (0.157) and Admixed American (0.167) populations, with East Asian frequency about 0.205. The discovery papers measured 0.33 in a Dutch sample and about 10% 1298CC homozygotes in a Canadian sample — the same ballpark, a quarter-century apart.

Position, mechanism and strength. C677T (rs1801133, Ala222Val) sits in exon 4, in the enzyme’s catalytic core; it destabilises the FAD cofactor and the enzyme’s quaternary structure, producing a thermolabile enzyme with about half of normal activity in TT homozygotes and a clear homocysteine elevation when folate status is low. A1298C sits in exon 7, in the regulatory domain; it retains about 68% of wild-type activity in recombinant expression, is not thermolabile, and its purified protein is biochemically indistinguishable from normal. In short: C677T is the stronger, better-understood variant; A1298C is the milder, less mechanically understood one — and most of the internet’s “MTHFR” content is really C677T content.

On its own, the honest answer is: weakly at most, and inconsistently. The 1998 discovery study found neither 1298CC nor 1298AC carriers had higher homocysteine or lower folate. The Family Heart Study found the 1298 mutation alone did not raise homocysteine — only double heterozygotes (one 677T plus one 1298C) differed. In the largest dataset (10,601 Norwegians) the variant did reach statistical significance for homocysteine, folate and betaine associations, but far more weakly than C677T. And in a 2025 Chinese hypertensive cohort, adequate folate and B12 status markedly blunted the genotypic effect altogether. Any A1298C-alone effect on homocysteine is small, inconsistent, and dwarfed by C677T and by vitamin status.

Carrying one copy of each variant — one 677T allele and one 1298C allele. About 15% of a Canadian sample were compound heterozygotes, with enzyme activity of 50–60% of control, lower than single-variant carriers; the Family Heart Study found fasting homocysteine significantly higher in double heterozygotes than in carriers of the 677 variant alone. Notably, no individual homozygous for both variants has been observed. The discovery-era neural-tube-defect signal for compound heterozygosity (odds ratio 2.04) was not statistically significant, and current ACMG guidance holds that MTHFR polymorphism testing — for either variant — has minimal clinical utility and no place in routine thrombophilia evaluation.

Both raise folate status; neither has an outcomes-trial advantage. 5-MTHF reliably produces equal-or-better folate-status biomarkers and little-to-no unmetabolised folic acid (UMFA); folic acid lowers homocysteine equally in every genotype studied and is the only form with hard-outcome neural-tube-defect evidence behind fortification. Whether chronic low-level UMFA harms anyone is unresolved — the Framingham authors’ own words are that the consequences are unknown. Two honest caveats: human liver DHFR activates folic acid slowly (under 2% of the rat rate, with wide individual variation), and a 2026 feasibility trial caught 5-MTHF degrading in retained supplement samples — the “natural” vitamer is the less stable molecule. No RCT has shown superior clinical outcomes for 5-MTHF over folic acid.

No — and that is the honest negative. A ClinicalTrials.gov query for MTHFR A1298C (2026-08-09) returns no currently recruiting A1298C-specific interventional trial. The big genotype-stratified prevention programme now recruiting, CSPPT-2 (NCT04974151 and NCT04974138), is stratified by C677T, not A1298C. A genotype-personalised B-vitamin trial in hyperhomocysteinemia (NCT06264570) and a maternal methyl-nutrient cohort (NCT07568561) are recruiting adjacent questions. This site tracks the registered record as it changes; enrolment decisions belong with a clinician.

Very little, and here is exactly what: this site sets no cookies and runs no cross-site trackers. A cookieless statistics beacon counts page views, time-on-page, scroll depth, first pointer activity and outbound-link destination hosts, sent to a same-origin collector. The collector stores no IP addresses — it keeps a daily-rotating salted hash of the visitor IP, so unique visitors can be counted within a day but no one can be tracked across days. No personal profiles are built, nothing is sold or shared, and the beacon honours the Do Not Track browser signal by sending nothing at all when it is set.